A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

By afschroeder • August 15, 2025

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer. Lung Cancer. 2025 Aug 6;207:108701. doi: 10.1016/j.lungcan.2025.108701. Epub ahead of print. PMID: 40811940.

Tags: Alectinib, anaplastic lymphoma kinase, chemotherapy, Costs and Cost Analysis, Hematology/Oncology, Non-small cell lung cancer, Publications, Pulmonary, Critical Care & Sleep Medicine, Statistical model, Tyrosine kinase inhibitors

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus

Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran[...]

The Next Chapter of Cancer Immunology Research

Jaffee EM, Ribas A. The Next Chapter of Cancer Immunology Research. Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158/2326-6066.CIR-25-1391. PMID: 41502310.

Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review

Hu EH. Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review. Cureus. 2025 Dec 4;17(12):e98484. doi: 10.7759/cureus.98484. PMID:[...]